Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.

Fonte JS, Robles JF, Chen CC, Reynolds J, Whatley M, Ling A, Mercado-Asis LB, Adams KT, Martucci V, Fojo T, Pacak K.

Endocr Relat Cancer. 2012 Feb 13;19(1):83-93. doi: 10.1530/ERC-11-0243. Print 2012 Feb.

2.

Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.

van Berkel A, Rao JU, Lenders JW, Pellegata NS, Kusters B, Piscaer I, Hermus AR, Plantinga TS, Langenhuijsen JF, Vriens D, Janssen MJ, Gotthardt M, Timmers HJ.

J Nucl Med. 2015 Jun;56(6):839-46. doi: 10.2967/jnumed.115.154815. Epub 2015 Apr 16.

3.

Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.

Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, Adams KT, Solis D, Lenders JW, Pacak K.

J Clin Oncol. 2007 Jun 1;25(16):2262-9.

4.

Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.

Zelinka T, Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Reynolds JC, Ling A, Eisenhofer G, Lazúrová I, Adams KT, Whatley MA, Widimsky J Jr, Pacak K.

Endocr Relat Cancer. 2008 Mar;15(1):311-23. doi: 10.1677/ERC-07-0217.

5.

Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.

Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, Eisenhofer G, Martiniova L, Adams KT, Pacak K.

J Clin Endocrinol Metab. 2009 Dec;94(12):4757-67. doi: 10.1210/jc.2009-1248. Epub 2009 Oct 28.

6.

Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations.

King KS, Prodanov T, Kantorovich V, Fojo T, Hewitt JK, Zacharin M, Wesley R, Lodish M, Raygada M, Gimenez-Roqueplo AP, McCormack S, Eisenhofer G, Milosevic D, Kebebew E, Stratakis CA, Pacak K.

J Clin Oncol. 2011 Nov 1;29(31):4137-42. doi: 10.1200/JCO.2011.34.6353. Epub 2011 Oct 3.

7.

Metastatic pulmonary pheochromocytomas: positive I-123 MIBG SPECT with negative I-131 MIBG and equivocal I-123 MIBG planar imaging.

Tsuchimochi S, Nakajo M, Nakabeppu Y, Tani A.

Clin Nucl Med. 1997 Oct;22(10):687-90.

PMID:
9343724
8.

The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma.

Meyer-Rochow GY, Schembri GP, Benn DE, Sywak MS, Delbridge LW, Robinson BG, Roach PJ, Sidhu SB.

Ann Surg Oncol. 2010 Feb;17(2):392-400. doi: 10.1245/s10434-009-0850-5. Epub 2009 Dec 1.

PMID:
19949879
9.

Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.

Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, King KS, Rao JU, Wesley RA, Adams KT, Pacak K.

J Natl Cancer Inst. 2012 May 2;104(9):700-8. doi: 10.1093/jnci/djs188. Epub 2012 Apr 18.

10.

Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial.

Wiseman GA, Pacak K, O'Dorisio MS, Neumann DR, Waxman AD, Mankoff DA, Heiba SI, Serafini AN, Tumeh SS, Khutoryansky N, Jacobson AF.

J Nucl Med. 2009 Sep;50(9):1448-54. doi: 10.2967/jnumed.108.058701. Epub 2009 Aug 18.

11.

Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.

Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milosevic D, Mannelli M, Linehan WM, Adams K, Timmers HJ, Pacak K.

Eur J Cancer. 2012 Jul;48(11):1739-49. doi: 10.1016/j.ejca.2011.07.016. Epub 2011 Oct 28.

13.

A comparison of the performance of ⁶⁸Ga-DOTATATE PET/CT and ¹²³I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma.

Maurice JB, Troke R, Win Z, Ramachandran R, Al-Nahhas A, Naji M, Dhillo W, Meeran K, Goldstone AP, Martin NM, Todd JF, Palazzo F, Tan T.

Eur J Nucl Med Mol Imaging. 2012 Aug;39(8):1266-70. doi: 10.1007/s00259-012-2119-7. Epub 2012 Apr 20.

PMID:
22526961
14.

6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.

Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, Schadmand-Fischer S, Bartenstein P, Lackner KJ, Klöppel G, Schreckenberger M, Weber MM.

J Clin Endocrinol Metab. 2010 Jun;95(6):2800-10. doi: 10.1210/jc.2009-2352. Epub 2010 Apr 6.

PMID:
20371665
15.

68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours.

Naji M, Zhao C, Welsh SJ, Meades R, Win Z, Ferrarese A, Tan T, Rubello D, Al-Nahhas A.

Mol Imaging Biol. 2011 Aug;13(4):769-75. doi: 10.1007/s11307-010-0396-8.

PMID:
20700766
16.

Use of 131I-MIBG scintigraphy in the evaluation of suspected pheochromocytoma.

Swensen SJ, Brown ML, Sheps SG, Sizemore GW, Gharib H, Grant CS, van Heerden JA.

Mayo Clin Proc. 1985 May;60(5):299-304.

PMID:
3990377
17.

Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.

Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, Damon L, Linker C, Sznewajs A, Shiboski S, Fitzgerald P.

J Clin Oncol. 2009 Sep 1;27(25):4162-8. doi: 10.1200/JCO.2008.21.3496. Epub 2009 Jul 27.

18.

[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas.

van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP, Bosman FT, Kwekkeboom DJ.

J Clin Endocrinol Metab. 2001 Feb;86(2):685-93.

PMID:
11158032
19.

6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.

Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, Jager PL, Elsinga PH, Dierckx RA, van der Wal JE, Sluiter WJ, de Vries EG, Links TP.

J Clin Endocrinol Metab. 2009 Oct;94(10):3922-30. doi: 10.1210/jc.2009-1054. Epub 2009 Jul 21.

PMID:
19622618
20.

Does iodine-131 meta-iodobenzylguanidine (MIBG) scintigraphy have an impact on the management of sporadic and familial phaeochromocytoma?

Taïeb D, Sebag F, Hubbard JG, Mundler O, Henry JF, Conte-Devolx B.

Clin Endocrinol (Oxf). 2004 Jul;61(1):102-8.

PMID:
15212651
Items per page

Supplemental Content

Write to the Help Desk